Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized crossover PK study of MK-0616 in healthy Japanese, Chinese, and Caucasian adults
jRCT2031220322Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of enlicitide in hypercholesterolemia, sponsored by Merck & Co. Primary endpoint: Primary pharmacokinetics comparison between ethnic groups. Started Oct 2022; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on jRCT2031220322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220322.